Philips

PHG

市值 US$252億

October 15, 2026 Five-year research project unites 42 public and private partners across 17 countries to conduct 22 clinical studies involving 14,000+ patients; first patients will be enrolled this month Project aims to help cardiac patients avoid deterioration through early, personalized interventions delivered across the cardiac care journey Interventions will be co-created with patients and designed to systematically address socioeconomic, sex- and gender-related and digital access gaps With a total budget of EUR 27.6 million, the project is co-funded by the European Union Innovative Health Initiative (IHI) and industry partners Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the five-year EXIT-CVD research project, co-funded by the European Union Innovative Health Initiative (IHI) and the industry partners. The research consortium is led by University Medical Center Groningen (UMCG) and Philips, and aims to transform how cardiovascular disease is detected, monitored and treated.

AMSTERDAM--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in oral healthcare, today announced the formation of the Philips Sonicare Global Clinical Advisory Board, a group of external oral healthcare experts established to help shape the future of Philips Oral Healthcare through science, clinical insight and meaningful innovation. The board brings together 12 international experts with complementary expertise across clinical practice, research, education, behavior change.

CAMBRIDGE, Mass. & MCCOMB, Miss.--(BUSINESS WIRE)--Royal Philips, a global leader in health technology and Southwest Mississippi Regional Medical Center (SMRMC), which serves as the hub of Southwest Health, today announced that the hospital has installed the first Philips Rembra CT system for acute and high-demand imaging environments in the United States. The new system is designed to support the McComb hospital's high-demand emergency imaging environment with the goal of expanding local acces.

September 16, 2026 SYMPHONY receives ITEA's highest excellence award for connected healthcare ecosystems AI FORSchung is recognized for innovation in AI-powered fiber-optic sensing Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that two Philips-led public-private research collaborations have received ITEA Awards of Excellence 2026 for advancing AI-enabled innovation in healthcare. SYMPHONY received the ITEA Award of Excellence for “Exceptional Excellence” for connecting healthcare data, clinical workflows and AI-supported decision tools through open, interoperable ecosystems.

In a breathtaking display, Red Bull athlete Marco Waltenspiel and his distinctive moustache achieved a world's first in wingsuit hot-air balloon slalom, soaring between seven hot-air balloons at 200 km/h, to celebrate the freedom to be yourself and follow your passions. AMSTERDAM, Sept.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, this month launched the Philips Lumea IPL 9900 Pro, transforming at-home hair removal into a personalized and rewarding self-care routine. Philips Lumea IPL 9900 Pro is the first at-home IPL with audio feedback and motion guidance that talks to users2, helping give them greater confidence in effective treatment. As the world's no. 1 IPL brand3, Philips brings 25 years of IPL research a.

PHG broadens women's health ultrasound portfolio with the eV14-2v, offering enhanced imaging, a lighter design and remote collaboration.

PHG's AI-powered 3D Auto CFQ shows stronger agreement with cardiac MRI than 2D PISA, supporting its cardiovascular ultrasound strategy.

September 3, 2026   FDA 510(k) cleared and CE marked, the eV14-2v combines exceptional image quality and broad clinical capabilities in one lightweight transducer, helping streamline exams, support diagnostic confidence, and improve the patient experience Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced the eV14-2v transvaginal transducer, expanding its obstetrics and gynecology ultrasound portfolio. FDA 510(k) cleared and CE marked, the eV14-2v is designed to support a broad range of gynecology and early obstetrics exams by combining image quality and broad clinical capabilities in a single lightweight transducer.

August 27, 2026 The solution combines Philips' high-performance 1.5T MRI platform and advanced interventional workflow capabilities with Imrico r' s exclusive portfolio of systems and consumables for MR-guided cardiac interventions. Amsterdam, the Netherlands – August 27, 2026: Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR.